Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Conditions: Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: OBP-301; Drug: Pembrolizumab Sponsors: Weill Medical College of Cornell University; Merck Sharp& Dohme LLC; Oncolys BioPharma Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma
Conditions: Gastric Cancer Sponsors: Fujian Medical University; Fujian Medical University Union Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic Adenocarcinoma
Conditions: Pancreatic Neoplasms Interventions: Procedure: surgery or diagnostic staging laparoscopy Sponsors: First Affiliated Hospital, Sun Yat-Sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
Conditions: Neuroendocrine Neoplasm; Adenocarcinoma Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8 Interventions: Biological: Balstilimab; Procedure: Biospecimen Collection; Biological: Botensilimab; Procedure: Computed Tomography; Other: Dietary Intervention; Procedure: Magnetic Resonance Imaging; Dietary Supplement: Vitamin C Sponsors: University of Southern California; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Conditions: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab; Drug: Chemotherapy Sponsors: UNICANCER; National Cancer Institute, France; GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Fruquintinib in combination with Sintilimab and CAPEOX Sponsors: Henan Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Pancreatic Cancer Screening in a Population at High Risk
Conditions: Pancreatic Ductal Adenocarcinoma; Hereditary Diseases; Pancreatitis, Chronic Interventions: Procedure: endoscopic ultrasonography; Procedure: magnetic resonance; Diagnostic Test: laboratory examination Sponsors: Masaryk Memorial Cancer Institute; Masaryk University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Conditions: Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Other: Contrast Agent; Drug: Leuprolide; Procedure: Magnetic Resonance Imaging; Other: Physical Performance Testing; Drug: Relugolix Sponsors: Ohio State University Comprehensive Cancer Center; Pfizer; Myovant Sciences GmbH; Sumitomo Pharmaceuticals America Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
Conditions: Rectal Cancer; Rectal Adenocarcinoma Interventions: Procedure: Nonoperative surveillance Sponsors: Tampere University Hospital; Tampere University; Helsinki University Central Hospital; Turku University Hospital; Kuopio University Hospital; Oulu University Hospital; Jyv äskylä Central Hospital; Seinajoki Central Hospital; Satakunta Central Hospital; North Karelia Central Hospital; Tartu University Hospital; East Tallinn Central Hospital; West Tallinn Central Hospital; North Estonia Medical Centre Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer
Conditions: Localized Prostate Adenocarcinoma; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8 Interventions: Procedure: Computed Tomography; Procedure: Cone-Beam Computed Tomography; Radiation: Image-Guided Adaptive Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Stereotactic Ablative Radiotherapy; Other: Survey Administration Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Conditions: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma Interventions: Drug: Zongertinib; Drug: Trastuzumab deruxtecan; Drug: Trastuzumab emtansine Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Ductal Adenocarcinoma Interventions: Other: Blood sample Sponsors: Roswell Park Cancer Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions: Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Interventions: Drug: IBI343 combined with IBI308 Sponsors: Harbin Medical University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Conditions: Colorectal Cancer; Colorectal Neoplasms; Colorectal Adenocarcinoma; Colorectal Cancer Stage I; Colorectal Neoplasms Malignant; Colorectal Cancer Recurrent Interventions: Other: Tw1CE Sponsors: City of Hope Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
